

AD_____

Award Number: W81XWH-06-1-0628

TITLE: Novel Transgenic Mouse Model for Testing the Effect of Circulating IGF-I on Mammary Stem/Progenitor Cell Number and Tumorigenesis

PRINCIPAL INVESTIGATOR: Adrian V. Lee

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, TX 77030

REPORT DATE: August 2008

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-08-2008		2. REPORT TYPE Final		3. DATES COVERED (From - To) 24 Jul 2006-23 Jul 2008	
4. TITLE AND SUBTITLE Novel Transgenic Mouse Model for Testing the Effect of Circulating IGF-I on Mammary Stem/Progenitor Cell Number and Tumorigenesis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0628	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Adrian V. Lee E-Mail: avlee@breastcenter.tmc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, TX 77030				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Epidemiological evidence indicates that high levels of circulating IGF-I (within the normal range) predict risk of breast cancer. To examine this experimentally, investigators have previously injected mice with IGF-I and shown that this increases mammary cancer incidence and progression. However, injection of IGF-I may create non-physiological peaks of IGF-I in the circulation. In this proposal we tested whether transgenic mice (TTR-IGF-I) that had a 30% increase in circulating levels of IGF-I (via liver specific expression) had altered ErbB2-induced mammary tumorigenesis. We found no difference in time to tumor formation in ErbB2 vs. TTR-IGF-I/ErbB2 transgenic mice. Our conclusion is either that ErbB2-induced tumorigenesis is insensitive to circulating IGF-I, or other studies using injected IGF-I were confounded by the transient spike in IGF-I caused by the non-physiologic method of administration. Further studies using additional mouse models are required to definitively address a role for circulating IGF-I in mammary tumorigenesis, however, our data suggest that the IGF-I may not directly regulate risk, but rather may be an indicator of another risk factor.					
15. SUBJECT TERMS No subject terms provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	7	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	1
Key Research Accomplishments.....	4
Reportable Outcomes.....	4
Conclusion.....	4
References.....	4

A) INTRODUCTION

Epidemiological evidence indicates that women with IGF-I levels at the higher end of the normal range have increased risk of breast cancer¹. A better understanding of IGFs endocrine action in breast cancer may lead to the development of new and better therapies to reduce breast cancer incidence and increase survival by lowering serum IGF-I levels.

A recent publication in Science, has shown that the loss of imprinting of IGF-II (which causes an increase in circulating IGF-II and causes increased body growth) alters intestinal maturation and tumorigenesis by increasing the stem/progenitor cell population². Given that IGF-I is clearly involved in cancer progression (via its regulation of apoptosis and proliferation) this new evidence indicating a possible role in stem/progenitor cells, puts IGFs at a critical intersection of many aspects of tumorigenesis. Clearly, studies on the effect of IGF-I on stem cell survival in breast cancer are limited, at best, and require novel *in vivo* approaches to decipher any causal relationship.

We hypothesized that *circulating liver-produced endocrine IGF-I can reach and stimulate the normal mammary gland, and that this will increase stem/progenitor cell number, and increase tumorigenesis in a mouse that has a predisposing oncogene.*

In this concept award we proposed the following specific aims:

1. Analyze the effect of circulating IGF-I levels on mammary stem/progenitor cells using flow sorting and transplantation assays.
2. Examine in mouse models whether increased circulating levels of IGF-I promote mammary tumor development in MMTV-ErbB2 transgenic mice, and if this is associated with increased stem/progenitor cell numbers in premalignant lesions and tumors.

B) BODY

Aim 1) Analyze the effect of circulating IGF-I levels on mammary stem/progenitor cells using flow sorting and transplantation assays.

Before starting complex mammary stem/progenitor and transplantation assays, we first confirmed that our transgenic mice had increased circulating IGF-I and examined if this affected mammary ductal development.

Transgenic mice that overexpress the mouse IGF-I gene in the liver (TTR-IGF-I), were found to have elevated circulating IGF-I (Figure 1). Transgenic female mice (941.22 ± 41.77 ng/ml) had a 27% increase in serum IGF-I levels compared to age matched wild-type littermate controls (743.69 ± 28.24 ng/ml). Importantly, this increase is similar to that which confers increased risk in women.




Figure 1. Increased circulating serum IGF-I levels in 6 week old female TTR-IGF-I transgenic mice. Transgenic TTR-IGF-I mice (black bar) had significantly higher ($p < 0.01$) circulating levels of IGF-I compared to wild type controls (red bar). Bars indicate the mean ($\pm$ SEM) serum levels of IGF-I assayed by IEMA. The number of animals is represented within the bars. $**p < 0.01$

An analysis of ductal development in these animals indicated no obvious alterations by whole mount analysis (Figure 2a) or histologically (Figure 2b). We concluded that increased systemic IGF-I had no effect on ductal outgrowth, ductal side branching or ductal structure by 6 weeks of age. This is consistent with a recent publication indicating that local production of IGF-I, and not circulating IGF-I, affects mammary gland development³.




Figure 2. No effect of circulating IGF-I on mammary ductal development at 6 weeks of age. A.) Representative whole mounts of the #4 inguinal mammary gland from wt (top panel) and transgenic (bottom panel). Note no change in ductal growth or branching (insert). B.) Representative wild

type (Wt; left panel) and TTR-IGF-I transgenic (Tg; right panel) mammary glands Hematoxylin and Eosin (H&E) stained by IHC. Magnification: 40x

To perform mammary gland transplantation assays to assess stem cell number and regeneration we needed to backcross the TTR-IGF-I mice into a uniform genetic background (we chose FVB/N), as these mice were on a mixed genetic background that would have caused rejection following transplantation. FVB/N was a convenient genetic strain as this is the strain for MMTV-ErbB2 mice we used to cross in Aim 2 (see next Aim). Following the long process of backcrossing we have now started to perform transplantation. Mammary glands were harvested from FVB/N-TTR-IGF-I mice at 6 weeks of age transplanted by limiting dilution into FVB/N mice which had the mammary fat pad cleared of epithelium at 3 weeks of age. We have performed two rounds of transplantation and are currently awaiting harvesting to determine the extent and percentage of transplants.

Aim 2) Examine in mouse models whether increased circulating levels of IGF-I promote mammary tumor development in MMTV-ErbB2 transgenic mice, and if this is associated with increased stem/progenitor cell numbers in premalignant lesions and tumors.

To study the effect of circulating levels of IGF-I on mammary tumor incidence we crossed our TTR-IGF-I (tg/wt) mice (F5 FVB/N backcross) with heterozygous MMTV-ErbB2 (tg/wt) and compared time to mammary tumor formation in the resulting offspring (Figure 3). Briefly, MMTV-ErbB2 mice are based on a mammary specific overexpression of the ErbB2 receptor, a frequently amplified oncogene in human breast cancer. The resulting offspring had one of 4 genotypes; increased systemic IGF-I only (tg/wt), mammary specific ErbB2 overexpression only (tg/wt), IGF-I and ErbB2 bigenic expression (tg/tg), or wild type controls (wt/wt).




Figure 3. Model depicting the genetically different mouse lines derived from TTR-IGF-I crossed with MMTV ErbB2. Note offspring are all virgins for tumor study.

To determine the penetrance of mammary tumor formation in these groups, we measured time to tumor formation (palpable tumor $>100\text{mm}^3$) and using Kaplan-Meier analysis (Figure 4). When tumors reached 1cm^3 in size, animals are injected with BrdU (100mg/kg) for 2 hrs, sacrificed, and mammary glands with tumors processed for paraffin blocks or frozen in liquid nitrogen. TTR-IGF-IxErbB2 bigenic virgin transgenic female mice showed palpable mammary tumors beginning at 24 weeks of age and with a mean time to tumor formation (MMTF) of 32 weeks (Figure 4). ErbB2 only virgin transgenic mice showed a similar tumor formation with the earliest mammary tumors palpated at 24 weeks of age and a MMTF of 33 weeks of age as depicted in Figure 4. Surprisingly, circulating levels of IGF-I did not seem have an affect on tumor incidence in females overexpressing ErbB2 compared to ErbB2 only animals. Mimicking the control group (wt/wt), a palpable tumor was not detected in the TTR-IGF-I mice.




Figure 4. Elevated circulating IGF-I (TTR-IGF-I) doesn't affect mammary tumor formation in MMTV-ErbB2 virgin mice.

Kaplan-Meier tumor curves that illustrate the percent of virgin bigenic ErbB2xIGF-I (green), ErbB2 only (blue), or IGF-I only (maroon) transgenic mice that are tumor free compared to wild type (WT; black) virgin controls. Note that there is no difference between the ErbB2 only and Bigenic groups, however both lines had significant increases in mammary tumor growth vs. wild type and IGF-I animals. In addition, circulating levels of IGF-I did not induce mammary tumor formation in the IGF-I only group. Steps on the graph indicate when a tumor was first palpated on each animal in the study. MMTF=mean time to tumor formation

Further analysis comparing the tumors from the ErbB2 only and bigenic group revealed that both had visible lung metastasis and approximately the same number of mammary tumors per animal (Table 1). A preliminary analysis of the time it took a tumor to reach approximately 1cm³, suggested that elevated IGF-I may stimulate a faster tumor growth rate in the bigenic (7 week average) compared to the ErbB2 only group (8.7 wk average). However, this data was confounded by different sizes at palpation and at harvesting (thus affecting time to reach 1cm³). The tumor growth curves were therefore analyzed by the Biostatistics core the Breast

	ErbB2 Only	IGF-1 x ErbB2
Number of Tumors	16(20) 80%	17(23) 74%
MTTF	33 wks/ 8.25m	32 wks/ 8m
Lung Metastasis	yes	yes
Av. # of Tumors per Animal	1.9	2.00
Av. Tumor Growth Rate	8.70 wks	7.01 wks

Center at BCM who used modeling of regression curves to estimate the time it took each tumor to double in size or reach 1cm³. This sophisticated and thorough biostatistical analysis revealed that there was absolutely no difference in the growth rates of the ErbB2 and IGF-IxERbB2 tumors.

Table 1. Physical comparison of tumor formation in ErbB2 only vs. bigenic (IGF-I x ErbB2) virgin females. Both group exhibit very similar tumor incidences, however IGF-I seems to induce a slightly more rapid tumor group. %= percentage of animals with tumors. Number in parenthesis indicates total number of animals per group/number out side parenthesis indicate number of animal per group with palpable tumors.

We were unable to detect any difference in mammary tumor incidence or growth when circulating IGF-I levels were increased. Indeed, an analysis of circulating IGF-I levels these mice confirmed that levels were elevated in the serum (Figure 5). Interestingly, however, IGF-I levels in the actual mammary glands were unchanged (Figure 5). This suggests that the elevated circulating IGF-I may not be able to reach the mammary gland, thus in part explaining why there was no change in time to mammary tumor formation. Surprisingly, mammary tumors from the bigenic ErbB2xIGF-I mice had significantly ($p < 0.05$) higher IGF-I protein levels compared to tumors from ErbB2 only females at the time of sacrifice (Figure 5 far right panel). This assay was performed with a kit that is for measuring total serum IGF-I. We have optimized a new kit developed for measuring low levels of IGF-I in tissue and are currently reproducing these results.




Figure 5. Comparison of IGF-I protein and serum levels in tumors and mammary glands from ErbB2 only and bigenic virgin females. Increased circulating levels on IGF-I resulted in significantly higher ($p < 0.05$) IGF-I protein levels in tumors from bigenic females compared to their respective normal mammary glands and to normal mammary glands

and tumors from ErbB2 only transgenics. Bars indicate the mean ($\pm$ SEM) serum or protein levels of IGF-I assayed by IMEA. * = $p < 0.05$.

SUMMARY

By crossing mice with elevated circulating IGF-I (TTR-IGF-I) with mice with a predisposing mammary specific oncogene (MMTV-ErbB2) we have provided evidence that circulating levels may not play a role in initiating mammary gland tumorigenesis. This raises significant questions regarding epidemiological studies indicate that circulating IGF-I levels predict breast cancer risk.

C) KEY RESEARCH ACCOMPLISHMENTS

- Elevated circulating IGF-I levels in TTR-IGF-I mice
- Increased circulating IGF-I doesn't alter mammary gland development in female virgin mice
- No change in time to tumor formation in TTR-IGF-IxMMTV-ErbB2 mice vs. MMTV-ErbB2 mice
- Preliminary evidence that TTR-IGF-IxErbB2 mammary tumors may grow faster than -ErbB2 tumors
- Evidence that TTR-IGF-IxErbB2 mammary tumors have increased levels of IGF-I compared to ErbB2 tumors

D) REPORTABLE OUTCOMES

None as yet

E) CONCLUSION

This study raises important questions regarding the epidemiological evidence suggesting that elevated circulating IGF-I is associated with increased breast cancer risk in humans, and experimental evidence showing that twice daily injection of IGF-I promotes mammary tumorigenesis and metastasis. Our data indicates that elevated circulating IGF-I doesn't alter ErbB2-induced tumorigenesis. Other studies that have examined circulating IGF-I and breast cancer risk in animal models have injected IGF-I and used different methods of mammary tumorigenesis including carcinogen (DMBA) or other oncogenes (SV40T antigen). Unfortunately, we can't directly compare our results with published studies due to the different methods of tumorigenesis, however, the conclusion is either that ErbB2-induced tumorigenesis is insensitivity to circulating IGF-I, or other studies using injected IGF-I were confounded by the transient spike in IGF-I caused by the non-physiologic method of administration. Further studies using additional mouse models are required to definitively address a role for circulating IGF-I in mammary tumorigenesis, however, our data suggest that circulating IGF-I may not directly regulate risk, but rather may be an indicator of another risk factor. Further studies are required to test this hypothesis.

F) REFERENCES

1. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. *Lancet* 2004; 363:1346-53.
2. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, Okano H, Ko MS, Ohlsson R, Longo DL, Feinberg AP. Loss of imprinting of *Igf2* alters intestinal maturation and tumorigenesis in mice. *Science* 2005; 307:1976-8.
3. Richards RG, Klotz DM, Walker MP, Diaugustine RP. Mammary gland branching morphogenesis is diminished in mice with a deficiency of insulin-like growth factor-I (IGF-I), but not in mice with a liver-specific deletion of IGF-I. *Endocrinology* 2004; 145:3106-10.
4. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, Ramos-Mejia V, Rouleau A, Yang J, Bosse M, Lajoie G, Bhatia M. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. *Nature* 2007.